ALDX
What one share of Aldeyra Therapeutics holds
Pharmaceutical Preparations
Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity.
Aldeyra Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.38 |
|---|---|
| Cash and investments | $0.75 |
| Debt | $0.25 |
| Book value | $0.63 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$1.65 | $0.00 | −$1.34 | — | $1.72 |
| 2017 | — | −$1.40 | $0.00 | −$1.21 | — | $2.07 |
| 2018 | — | −$1.79 | $0.01 | −$1.39 | — | $3.30 |
| 2019 | — | −$2.24 | $0.00 | −$1.66 | — | $1.68 |
| 2020 | — | −$1.11 | — | −$1.10 | — | $1.54 |
| 2021 | — | −$1.07 | $0.00 | −$0.79 | — | $3.54 |
| 2022 | — | −$1.06 | $0.00 | −$0.97 | — | $2.58 |
| 2023 | — | −$0.64 | $0.00 | −$0.51 | — | $2.02 |
| 2024 | — | −$0.94 | — | −$0.73 | — | $1.19 |
| 2025 | — | −$0.56 | — | −$0.56 | — | $0.74 |